arXiv AI

Learning Clinical-Trial Strategy: Offline Policy Training for Decision Agents

arXiv:2608. 03606v1 Announce Type: new Abstract: Clinical development is sequential decision-making under uncertainty, where a sponsor must plan a portfolio of experiments from heterogeneous evidence.

arXiv AI
Aug 10

ResidencyRL: Reinforcement Learning in Simulated Clinical Environments

arXiv:2608. 07418v1 Announce Type: new Abstract: In medical education, physicians convert academic knowledge into clinical expertise through residency: years of training across thousands of encounters, with diverse sources of feedback and progressively greater autonomy.

By Valentin Li\'{e}vin, Samuel Schmidgall, Tim Strother, Alex Bijamov, Akshay Goel, Anil Palepu, Chunjong Park, Vahid Balazadeh, Min Woo Sun, Marius Guerard, Justin Chen, Dave Steiner, Vikram Dhillon, Ibrahim Azar, Akhil Mehta, Nicholas Spetsieris, Shilpan Shah, Maen Abdelrahim, Amit Dahiya, Yun Liu, Katherine Chou, Yossi Matias, Avinatan Hassidim, Dale R. Webster, Quoc V. Le, Raia Hadsell, Joelle Barral, Carey Radebaugh, Aleksandra Faust, Shekoofeh Azizi, Mike Schaekermann, Po-Hsuan Cameron Chen, Tao Tu, David Racz, Lin Yang
arXiv AI
Jun 30

An AI agent for treatment reasoning over a biomedical tool universe

arXiv:2606. 28692v1 Announce Type: new Abstract: Treatment reasoning underpins every therapeutic decision, integrating disease context, comorbidities, medications, contraindications, and evolving biomedical knowledge to select an appropriate therapy.

By Shanghua Gao, Ayush Noori, Richard Zhu, Curtis Ginder, Zhenglun Kong, Xiaorui Su, Justin Kauffman, Benjamin S. Glicksberg, Joshua Lampert, Ankit Sakhuja, Ashwin Sawant, ATHENA-R1 Evaluation Consortium, David A. Clifton, Noa Dagan, Ran Balicer, Marinka Zitnik
arXiv Machine Learning
Jun 3

Fairness Definitions and Metrics in Deep Reinforcement Learning for Drug Discovery in Healthcare: A Rapid Evidence Review

arXiv:2606. 02902v1 Announce Type: cross Abstract: Deep reinforcement learning (DRL) is increasingly applied to de novo molecular design, but choices in data, rewards, and evaluation can yield uneven performance across disease areas and chemotypes.

By Esmaeil Shakeri, Ronnie de Souza Santos, Behrouz Far
arXiv Machine Learning
Jun 25

Neglected Free Lunch from Post-training: Progress Advantage for LLM Agents

arXiv:2606. 26080v1 Announce Type: new Abstract: Process reward models enable fine-grained, step-level evaluation of LLMs, yet building them for agentic settings remains prohibitively difficult: long-horizon interactions, irreversible actions, and stochastic environment feedback make both human annotation and Monte Carlo estimation infeasible at scale.

By Changdae Oh, Wendi Li, Seongheon Park, Samuel Yeh, Tanwi Mallick, Sharon Li